Kyphoplasty/vertebroplasty: Indications and Outcomes | How do GLP1s Affect Sarcopenia and MBD/OP?
Includes a Live Web Event on 04/12/2026 at 10:00 AM (EDT)
Kyphoplasty/vertebroplasty: Indications and Outcomes
Daniel Holzwanger, MD
Sunday, April 12, 2026, 10:00am to 10:30am Eastern Time (NY/USA)
How do GLP1s Affect Sarcopenia and MBD/OP
Shirine E. Usmani, MD, PhD, FRCPC
Sunday, April 12, 2026, 10:30am to 11:00am Eastern Time (NY/USA)
Description
GLP-1 receptor agonists are now widely used for the management of diabetes and overweight/obesity. Concerns have been raised about their potential impact on skeletal muscle and bone density. This talk will look at the evidence to date regarding how this class of medication impacts bone and muscle health and will highlight future areas of investigation.
Daniel Holzwanger, MD
Weill Cornell Medicine
Shirine E. Usmani, MD, PhD, FRCPC
Assistant Professor, Clinician Investigator and Staff Physician
University of Toronto, University Health Network, Toronto ON
Dr. Shirine Usmani completed her undergraduate degree in Physiology and Pharmacology at Western University before entering the MD/PhD program, also at Western. Her PhD focused on musculoskeletal health, specifically understanding molecular mechanisms involved in bone development and osteoarthritis. Dr. Usmani then went on to complete her residency training in Internal Medicine with a sub-specialization in Endocrinology at the University of Toronto. She completed a Post-Doctoral Fellowship through Toronto's Clinician Scientist Training Program with a focus on sarcopenia and genetic regulators of muscle mass. In October 2024 she started a full-time position as a Clinician Investigator/Assistant Professor at the University Health Network (UHN)/University of Toronto. Her research focuses on clinical and translational research through the UHN Osteoporosis and Metabolic Bone clinic.